Prelude Therapeutics Inc
PRLD
Get informed when a big investor buys or sells
+ FollowMarket Cap$223.18M
Close$
$1.02
72.2% downside
Current Fair Value
72.2% downsideOvervalued by 72.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $223.18 Million |
|---|---|
| Enterprise Value | $250.09 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.29 |
| Beta | 1.1 |
| Outstanding Shares | 82,519,981 |
Return
| Return on Equity | -129.27% |
|---|---|
| Return on Assets | -65.03% |
| Return on Invested Capital | -107.09% |
Valuation & Multiples
| P/E Ratio | -4.16 |
|---|---|
| PEG | 6.15 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 14.96 |
| Enterprise Value to EBIT | -3 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.19 |
| Debt to Equity | 0.81 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 12, 2026
EPS Estimate
$-0.27
Average shareholder expectationRevenue Estimate
$4.58 M
Average shareholder expectationNext Earnings Call
Expected Date
August 13, 2026
EPS Estimate
$-0.23
Average shareholder expectationRevenue Estimate
$4.78 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | 21,000▲ Infinity% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 39.99%▲ 2.59% |
|---|---|
| Total Invested | $105.24M▲ 27.46% |
| Investors Holding | 56▲ 7.00% |
ESG Score
No data
About Prelude Therapeutics Inc
68 employeesPrelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. The Company’s lead product candidates are designed to be oral, potent, and selective inhib...